Synergistic Anti-Cancer Activity of Melittin and Erlotinib in Non-Small Cell Lung Cancer
International Journal of Molecular Sciences · 22.03.2025 · 26 (7) · 2903
DOI: 10.3390/ijms26072903 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 22.03.2025. Verfasst von Hairulislam M Ibrahim und 4 weiteren Autor:innen. Beteiligte Einrichtung: Biological Science Department, College of Science, King Faisal University, P.O. Box 400, Al-Ahsa 31982, Saudi Arabia. Hauptthemen laut MEDLINE: Melitten, Erlotinib Hydrochloride, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Deanship of scientific research, King Faisal University, Saudi Arabia for funding this research work through the project number (GRANT4547).)., Deanship of Scientific Research, Vice Presidency for Graduate Studies and Scientific Research, King Faisal University, Saudi Arabia.
Abstract (Originalsprache)
Lung cancer remains a leading cause of cancer-related mortality worldwide. Despite advancements in current therapies, the development of drug resistance and the need for improved treatment outcomes necessitate the exploration of novel therapeutic approaches. This study aimed to investigate the synergistic anti-cancer effects of Melittin, a bee venom peptide, in combination with Erlotinib, an EGFR inhibitor, in non-small cell lung cancer (NSCLC). The study evaluated the combined effects of Melittin and Erlotinib on A549 NSCLC cells. Cell viability, proliferation, migration, and apoptosis were assessed using standard in vitro assays. Mechanistic studies investigated the impact of the combination treatment on key signaling pathways, including those involving JAK2 and JAK3. Molecular docking simulations were performed to predict the binding interactions between Melittin and these kinases. The combination of Melittin and Erlotinib significantly inhibited A549 cell proliferation and migration, with a marked reduction in cell viability and enhanced apoptosis compared to either agent alone. Mechanistically, Melittin demonstrated interactions with JAK2 and JAK3, key proteins involved in apoptotic signaling. Molecular docking simulations further supported these findings, predicting strong binding affinities between Melittin and both kinases. These findings demonstrate a synergistic anti-cancer effect of Melittin and Erlotinib in A549 NSCLC cells. The observed interactions with JAK2 and JAK3 suggest a potential mechanism for Melittin’s activity. These results highlight the potential of Melittin as a promising adjuvant to Erlotinib for the treatment of NSCLC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Biological Science Department, College of Science, King Faisal University, P.O. Box 400, Al-Ahsa 31982, Saudi Arabia.
ORCID-Profile: Ashraf Khalifa
Förderung
- Deanship of scientific research, King Faisal University, Saudi Arabia for funding this research work through the project number (GRANT4547).).
- Deanship of Scientific Research, Vice Presidency for Graduate Studies and Scientific Research, King Faisal University, Saudi Arabia
Zitieren
APA
Ibrahim, H. M., Alessa, J., Khalil, H. B., Bekhet, G. A., & Khalifa, A. (2025). Synergistic Anti-Cancer Activity of Melittin and Erlotinib in Non-Small Cell Lung Cancer. International Journal of Molecular Sciences, 26(7), 2903. https://doi.org/10.3390/ijms26072903
Vancouver
Ibrahim HM, Alessa J, Khalil HB, Bekhet GA, Khalifa A. Synergistic Anti-Cancer Activity of Melittin and Erlotinib in Non-Small Cell Lung Cancer. International Journal of Molecular Sciences. 2025;26(7):2903. doi:10.3390/ijms26072903
BibTeX
@article{Ibrahim2025,
author = {Ibrahim, Hairulislam M and Alessa, Jihad and Khalil, Hala Badr and Bekhet, Gamal A and Khalifa, Ashraf},
title = {Synergistic Anti-Cancer Activity of Melittin and Erlotinib in Non-Small Cell Lung Cancer},
journal = {International Journal of Molecular Sciences},
year = {2025},
volume = {26},
number = {7},
pages = {2903},
doi = {10.3390/ijms26072903}
}
EUVIMED